Palbociclib

SAN DIEGO, April 22, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to 22, 2026, in San Diego, USA. The presentations span multiple key innovation areas, including the pan-KRAS inhibitor ABSK211, the 4 th generation EGFR inhibitor ABK-EGFR-1, the CDK4 selective inhibitor ABK-CDK4, the MTA-cooperative PRMT5 inhibitor ABSK131, as well as a ctDNA-based study investigating resistance mechanisms to the FGFR2/3 inhibitor ABSK061. pan-KRAS Inhibitor ABSK211 ABSK211 is a potent, highly selective, and orally bioavailable small-molecule pan-KRAS inhibitor developed by Abbisko Therapeutics. It demonstrates broad inhibitory activity against multiple KRAS mutations, addressing significant unmet medical needs in KRAS-driven cancers. At AACR 2026, Abbisko presented preclinical data for both monotherapy and combination strategies of ABSK211. Monotherapy: Broad and Potent Inhibition Across KRAS Mutations KRAS mutations are highly prevalent across multiple cancers, including pancreatic (~90%), colorectal (~35%), and lung cancer (~25%). While several pan-KRAS inhibitors have entered clinical development, there remains a critical need for enhanced potency. In preclinical studies, ABSK211 demonstrated: Robust in vitro activity: ABSK211 significantly reduced cell viability across multiple KRAS alterations (including G12, G13, Q61, and WT amplification) at sub-nanomolar to nanomolar concentrations. Meanwhile ABSK211 displayed marginal inhibition in KRAS wild-type cell line with normal copy. Strong in vivo efficacy: Oral administration induced deep tumor regression in multiple KRAS G12V xenograft models, with robust target engagement. Broad mutation coverage: Consistent and significant antitumor activity was observed in models harboring KRAS G12D/C/S and G13D mutations. These findings support the clinical advancement of ABSK211, which is currently undergoing IND-enabling studies. Poster Information Title: Preclinical characterization of ABSK211: A highly potent, orally bioavailable and selective pan-KRAS inhibitor with broad and robust activity in KRAS-driven tumors Time: April 22, 2026, 9:00 AM – 12:00 PM (PT) Location: Poster Section 13, Board #10 Abstract #: 7090 Combination Therapy: Multi-Mechanistic Synergy Enhances Antitumor Activity Combination therapy is widely considered a key strategy to improve treatment outcomes in KRAS-mutant cancers. ABSK211 demonstrated synergistic antitumor activity with multiple therapeutic agents: In vitro synergy: Significant anti-proliferative synergy with PRMT5 inhibitors across KRAS mutations; strong synergy observed with EGFR monoclonal antibodies and chemotherapy in KRAS G12D/G12V models. Enhanced in vivo efficacy: Combination regimens with PRMT5 inhibitors, cetuximab, immunotherapies, and chemotherapy showed superior tumor growth inhibition and improved durability compared to monotherapy. These results demonstrate that ABSK211 can significantly enhance antitumor efficacy through multi-mechanistic synergy, supporting its further development in combination strategies. Poster Information Title: ABSK211, a highly potent and orally available pan-KRAS inhibitor, demonstrates robust antitumor efficacy in combination with multiple agents Time: April 22, 2026, 9:00 AM – 12:00 PM (PT) Location: Poster Section 13, Board #3 Abstract #: 7083 4 th Generation EGFR Inhibitor ABK-EGFR-1 ABK-EGFR-1 is a novel 4th generation EGFR inhibitor developed by Abbisko Therapeutics, specifically designed to target the EGFR C797S resistance mutation. It combines high selectivity with central nervous system (CNS) penetration to address key clinical challenges following resistance to 3rd generation EGFR TKIs. Targeting C797S-Mediated Resistance The EGFR C797S mutation is a clinically validated mechanism of resistance to third-generation EGFR TKIs, with an estimated 51,000–146,000 cases annually worldwide. Currently, no approved therapies specifically target this mutation, representing a significant unmet clinical need. Preclinical studies showed that ABK-EGFR-1: Exhibits high selectivity over wild-type EGFR and other kinases. Demonstrates significant in vivo antitumor activity in multiple EGFR C797S-driven xenograft models, effectively inhibiting tumor growth. Possesses excellent blood-brain barrier penetration and favorable drug-like properties. These findings support further development of ABK-EGFR-1 as a next-generation targeted therapy for EGFR-resistant cancers, particularly for patients with brain metastases. Poster Information Title: Discovery and characterization of ABK-EGFR-1, a 4th generation EGFR C797S Inhibitor with excellent selectivity and brain penetration Time: April 21, 2026, 2:00 PM – 5:00 PM (PT) Location: Poster Section 53, Board #7 Abstract #: LB350 CDK4 Selective Inhibitor ABK-CDK4 ABK-CDK4 is a highly selective, brain-penetrant small-molecule CDK4 inhibitor developed by Abbisko Therapeutics. It is designed to selectively target CDK4, reduce CDK6-related toxicity, and expand treatment potential for patients with brain metastases. Differentiation Through Selectivity and CNS Penetration 1st generation CDK4/6 inhibitors (e.g., palbociclib, ribociclib, and abemaciclib) have demonstrated clinical benefit in breast cancer, but CDK6 inhibition is associated with dose-limiting hematologic toxicities. In addition, 20–40% of breast cancer patients develop brain metastases, while current therapies have limited CNS exposure. Preclinical studies showed that ABK-CDK4: High selectivity: Over 50-fold selectivity for CDK4 versus CDK6, potentially reducing CDK6-related toxicity. CNS penetration: Favorable CNS exposure (Kpuu > 0.5) and drug-like properties. Antitumor activity: Effective inhibition of Rb phosphorylation and tumor growth in HR+/HER2− breast cancer models These results suggest that ABK-CDK4 may overcome key limitations of current CDK4/6 inhibitors and provide a differentiated therapeutic option. Poster Information Title: Discovery of ABK-CDK4, a selective and brain-penetrant CDK4 inhibitor Time: April 20, 2026, 9:00 AM - 12:00 PM (PT) Location: Poster Section 20, Board #13 Abstract #: 1905 MTA-cooperative PRMT5 inhibitor ABSK131 ABSK131 is a potent and selective small-molecule MTA-cooperative PRMT5 inhibitor developed by Abbisko Therapeutics, targeting MTAP-deleted tumors, and is currently in clinical development. Broad Synergy Across Multiple Therapeutic Modalities MTAP homozygous deletion occurs in approximately 10–15% of solid tumors and frequently co-exists with oncogenic drivers such as KRAS and EGFR. In addition, MTAP abnormities are associated with poor prognosis following standard-of-care therapies across multiple cancer types. Therefore, there remains a significant unmet need for novel and effective combination therapies centered on MTA-cooperative PRMT5 inhibitor for MTAP-deleted tumors, with the potential to enable precision patient stratification and deliver synergistic therapeutic benefits. Preclinical studies demonstrated that ABSK131 exhibits strong synergistic activity with multiple therapies: KRAS inhibitors: Enhanced tumor growth inhibition in KRAS-mutant, MTAP-deleted models when combined with AMG 510 or ABSK141. EGFR inhibitors: Improved anti-proliferative and in vivo antitumor activity in EGFR-mutant, MTAP-deleted NSCLC models when combined with osimertinib. MAT2A inhibitors: Consistent synergistic effects across multiple tumor models when combined with IDE397. Chemotherapy: Synergistic activity observed both in vitro and in vivo when combined with carboplatin in NSCLC models. These findings support ABSK131 as a potential backbone therapy for combination strategies in MTAP-deleted tumors. Poster Information Title: Synergistic antitumor activity of the MTA-cooperative PRMT5 inhibitor ABSK131 in combination with multiple therapeutic agents in diverse cancer models Time: April 21, 2026, 9:00 AM - 12:00 PM (PT) Location: Poster Section 14, Board #23 Abstract #: 4504 FGFR2/3 Inhibitor ABSK061 ABSK061 is a highly potent and selective small-molecule FGFR2/3 inhibitor developed by Abbisko Therapeutics. It has demonstrated encouraging efficacy and safety in Phase I studies and is currently being evaluated in a Phase II trial for gastric cancer. ctDNA Analysis Reveals Resistance Mechanisms Acquired resistance remains a major challenge limiting the long-term benefit of targeted therapies. Using ctDNA-based next-generation sequencing (NGS), Abbisko conducted longitudinal genomic analyses comparing baseline and progression samples to elucidate resistance mechanisms to ABSK061: On-target resistance: Polyclonal acquired FGFR2 mutations in the FGFR2 kinase domain were commonly observed in gastric cancer and cholangiocarcinoma. Off-target resistance: FGFR2-Atered NSCLC was prone to develop acquired alterations in genes involved in RTK/RAS pathways. These findings provide important molecular insights into resistance mechanisms and inform the design of future combination and sequential treatment strategies. Poster Information Title: Circulating tumor DNA (ctDNA)-based profiling of acquired resistance to the fibroblast growth factor receptor (FGFR)2/3 inhibitor lavengratinib(ABSK061) in patient(pt)s with advanced solid tumors Time: April 21, 2026, 9:00 AM - 12:00 PM (PT) Location: Poster Section 45, Board #14 Abstract #: 5319 At AACR 2026, Abbisko Therapeutics showcased the latest preclinical and translational research advances across multiple pipeline programs, demonstrating its strong capabilities in drug discovery and development. As these programs continue to advance into clinical stages, the company is further strengthening its globally competitive R&D platform. Looking ahead, Abbisko Therapeutics will continue to focus on addressing unmet medical needs and accelerating the translation of innovative discoveries into clinical applications, with the goal of delivering more first-in-class and best-in-class therapies to patients worldwide. SOURCE Abbisko Therapeutics 21% more press release views with Request a Demo

Group sales were +6% at constant exchange rates (CER) 1 , -5% when reported in CHF and +9% in USD 2 , in the first three months, driven by high demand for our innovative medicines and diagnostics. Pharmaceuticals Division sales were +7% at CER, -4% when reported in CHF and +10% in USD, due to continued high growth in sales of medicines for the treatment of severe diseases; Xolair (chronic hives, food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (severe eye diseases) and Ocrevus (multiple sclerosis) were the top growth drivers. Diagnostics Division sales were +3% at CER, -7% when reported in CHF and +7% in USD, as demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China. Highlights: Positive data for: fenebrutinib for multiple sclerosis (phase III), Gazyva/Gazyvaro for an autoimmune condition affecting kidney function (phase III); and petrelintide for obesity (phase II) CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis, representing a breakthrough in disease management Launch of the cobas MPX-E assay , a new 4-in-1 test to screen blood donors for HIV and hepatitis viruses Launch of the AI factory to accelerate the development of new therapeutics and diagnostics solutions Entry into a definitive agreement to acquire SAGA Diagnostics : SAGA’s proprietary cancer therapy response monitoring platform will strengthen Roche’s industry leading portfolio of oncology diagnostics and medicines Inauguration of the new research home for the Institute of Human Biology to enable scientists to pioneer human model systems for research Outlook for 2026 confirmed Roche CEO Thomas Schinecker : “We delivered a strong start to the year, achieving 6% Group sales growth at constant exchange rates. Our pipeline continued to advance in areas where patients face significant unmet need, including multiple sclerosis, obesity and a severe autoimmune disease that can lead to kidney failure. We also received EU approval for a new test to detect neuroinflammation in multiple sclerosis, marking a meaningful step forward in disease management. Our diversified portfolio across both divisions, together with continued pipeline progress, positions us well for sustained future growth in a dynamic geopolitical environment. We confirm our full-year outlook.” Outlook for 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend in Swiss francs. Sales CHF millions As % of sales % change January–March 2026 2025 2026 2025 At CER In CHF In USD Group 14,722 15,440 100.0 100.0 +6 -5 +9 Pharmaceuticals Division 11,469 11,949 77.9 77.4 +7 -4 +10 United States 5,693 6,224 38.7 40.3 +5 -9 Europe 2,234 2,320 15.2 15.0 -1 -4 Japan 649 671 4.4 4.3 +14 -3 International 2,893 2,734 19.6 17.8 +16 +6 Diagnostics Division 3,253 3,491 22.1 22.6 +3 -7 +7 International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others Group sales In the first three months of 2026, Roche sales were +6% at CER, -5% when reported in CHF, to CHF 14.7 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc against most currencies, notably the US dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates. Sales in the Pharmaceuticals Division were +7% at CER, -4% when reported in CHF, to CHF 11.5 billion, with medicines for severe diseases continuing their strong growth. The top five growth drivers – Xolair, Phesgo, Hemlibra, Vabysmo and Ocrevus – achieved total sales of CHF 5.3 billion, an increase of 14% at CER, or 2% in CHF, compared to the first three months of 2025. Sales of products with expired patents (Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra) decreased by a combined CHF 0.1 billion at CER, or CHF 0.2 billion in CHF. In the United States , sales were +5% at CER, -9% when reported in CHF, due to continued growth of Xolair and continuing uptake of Hemlibra, Polivy (blood cancer), Ocrevus and Vabysmo. This growth more than compensated for the lower sales of Perjeta (breast cancer) and Kadcyla (breast cancer). Sales in Europe were -1% at CER, or -4% when reported in CHF, due to lower sales of Polivy, the impact of biosimilar competition on Actemra/RoActemra and Perjeta (breast cancer) due to conversion to Phesgo. This decrease was partially offset by the demand for Ocrevus and Evrysdi (spinal muscular atrophy). In Japan , sales were +14% at CER, -3% when reported in CHF, mainly due to product supply to third parties, as well as a strong uptake of Hemlibra, Vabysmo and Polivy. Sales growth was partially offset by the decline in sales of Tamiflu and the impact of biosimilar erosion on Avastin. Sales in the International region were +16% at CER, or +6% when reported in CHF, led by Phesgo, Vabysmo, Polivy, Alecensa (lung cancer) and Ocrevus and partially offset by lower sales of influenza medicines Xofluza and Tamiflu. In China, sales were +14% at CER, or +5% when reported in CHF, as the uptake of Phesgo, Polivy and Vabysmo gained momentum following their inclusion in the government drug reimbursement list. The continued roll-out of Alecensa was the other growth driver. The increase was partially offset by lower sales of Xofluza and Perjeta. The Diagnostics Division’s sales were +3% at CER, -7% when reported in CHF, to CHF 3.3 billion as growth in demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China. Sales in the Europe, Middle East and Africa (EMEA) region were +3% at CER, -2% when reported in CHF, driven by higher sales of clinical chemistry and immunodiagnostic products. In North America , sales were +6% at CER, -7% when reported in CHF, with growth across core, pathology and molecular lab areas. Sales in Asia-Pacific were -5% at CER, or -15% when reported in CHF, due to the healthcare pricing reforms in China. In Latin America , sales growth was +10% at CER, or 0% when reported in CHF. Pharmaceuticals: key developments Compound Milestone Regulatory Gazyva/Gazyvaro Lupus FDA accepts application for Gazyva/Gazyvaro for the treatment of the most common form of lupus The filing was accepted based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE). If approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy to directly target B cells in SLE, potentially becoming the new standard of care for this condition. SLE is a potentially life-threatening autoimmune disease affecting more than three million people worldwide – achieving better disease control can reduce flares and may prevent irreversible organ damage. More information: Media Release , 21 April 2026 Giredestrant Breast cancer FDA accepts New Drug Application for giredestrant in ESR1-mutated, ER-positive advanced breast cancer Filing was accepted based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard-of-care endocrine therapy plus everolimus. Strength of evERA data demonstrates the potential for giredestrant combination to help address resistance to standard-of-care therapies, and that it could be the first and only oral SERD combination approved in the post-CDK4/6 inhibitor setting. The FDA has set a Prescription Drug User Fee Act date of 18 December 2026. More information: Media Release , 20 February 2026 Phase III, pivotal and other key read-outs Enspryng MOGAD Enspryng reduces risk of relapses by 68%, demonstrating potential to become first treatment for MOGAD The phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD is a rare autoimmune disease of the central nervous system characterised by unpredictable attacks of the optic nerves, spinal cord or brain that are often severe and debilitating. The data will be submitted to the regulatory authorities. More information: Media Release , 21 April 2026 Giredestrant Breast cancer Roche provides update on phase III persevERA study in ER-positive advanced breast cancer The persevERA breast cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed. Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment. The FDA recently accepted the New Drug Application based on evERA data; phase III lidERA data has been submitted to the FDA. More information: Media Release , 9 March 2026 Petrelintide Obesity Roche announces positive phase II results for petrelintide, an amylin analogue developed for people living with overweight and obesity Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value <0.001) while demonstrating placebo-like tolerability. At the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events. The data support further development of petrelintide in chronic weight management as monotherapy and its tolerability pro confirms its value as a combination partner. More information: Media Release , 5 March 2026 Fenebrutinib Multiple sclerosis Fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive multiple sclerosis (MS) in third positive phase III study (FENhance 1) FENhance 1 met its primary endpoint, showing that investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), which is consistent with FENhance 2 results showing 59% reduction. FENhance 1 is the final study read-out of the fenebrutinib pivotal clinical development programme in MS, following positive results for FENhance 2 in RMS and for FENtrepid in primary progressive multiple sclerosis (PPMS). Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology. More information: Media Release , 2 March 2026 Gazyva/Gazyvaro Membranous nephropathy Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in treatment of this autoimmune disease MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years. Up to 30% of people with membranous nephropathy progress to kidney failure over 10 years despite current treatment approaches; achieving complete remission can help delay or prevent this. Gazyva/Gazyvaro could become the first approved treatment for primary membranous nephropathy, having already achieved positive results in lupus nephritis, systemic lupus erythematosus and idiopathic nephrotic syndrome. More information: Media Release , 16 February 2026 Fenebrutinib Multiple sclerosis Fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS) Late-breaking phase III FENtrepid results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026 show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in reducing disability progression in PPMS. Fenebrutinib numerically reduced the risk of disability progression by 12% compared to Ocrevus as early as 24 weeks; additional analysis showed potential benefit in upper limb function. Fenebrutinib has the potential to become a first-in-class therapy in multiple sclerosis, as an oral, brain-penetrant BTK inhibitor for PPMS and relapsing multiple sclerosis (RMS) More information: Media Release , 7 February 2026 Other Institute of Human Biology Roche inaugurates new research home for the Institute of Human Biology (IHB), pioneering human model systems to accelerate drug discovery and development The new building is part of a CHF 1.4 billion site investment, reinforcing Roche’s commitment to Switzerland and the Basel life sciences cluster. The IHB enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients. Federal Councillor Elisabeth Baume-Schneider, Head of the Federal Department of Home Affairs (FDHA), attended the official opening ceremony. More information: Media Release , 23 March 2026 AI factory Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totalling more than 3,500 GPUs. The new computational infrastructure supports Roche’s vision of building an AI-accelerated healthcare organisation. NVIDIA AI factories help accelerate discoveries, enable more efficient clinical trials and unlock data insights at scale, ultimately advancing innovation and improved healthcare outcomes. More information: Media Release , 16 March 2026 Annual General Meeting Roche Annual General Meeting 2026 Shareholders approved all proposals of the Board of Directors. Severin Schwan was re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed. Shareholders approved an increase of the dividend to CHF 9.80 per share; this is the 39th consecutive dividend increase. Shareholders approved the exchange of non-voting equity securities ( Genussscheine ) for participation certificates. More information: Media Release , 10 March 2026 Gazyva/Gazyvaro Lupus New England Journal of Medicine publishes phase III ALLEGORY data showing Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms. Gazyva/Gazyvaro has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE). If approved, Gazyva/Gazyvaro would be the first type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity. More information: Media Release , 6 March 2026 Change in Enlarged Corporate Executive Committee Change to the Roche Enlarged Corporate Executive Committee Roche announced the appointment of Mark Dawson, MD, PhD, as the new Head of Roche Pharma Research and Early Development (pRED), effective 1 May 2026. Based in Basel, he will also become a member of the Enlarged Corporate Executive Committee. Mark Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research. A leading expert in cancer biology, his work on chromatin regulation and epigenetics has been instrumental in defining the molecular mechanisms that drive cancer initiation and progression. More information: Media Release , 17 February 2026 Pharmaceuticals sales Sales CHF millions As % of sales % change January–March 2026 2025 2026 2025 At CER In CHF Pharmaceuticals Division 11,469 11,949 100.0 100.0 +7 -4 United States 5,693 6,224 49.6 52.1 +5 -9 Europe 2,234 2,320 19.5 19.4 -1 -4 Japan 649 671 5.7 5.6 +14 -3 International 2,893 2,734 25.2 22.9 +16 +6 International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others Top 20 best-selling pharmaceuticals (% change at CER 1 ) Total United States Europe Japan International CHF m % CHF m % CHF m % CHF m % CHF m % Ocrevus Multiple sclerosis 1,692 +6 1,117 +3 363 +9 - - 212 +24 Hemlibra Haemophilia A 1,190 +13 613 +15 252 +5 81 +18 244 +14 Vabysmo Eye diseases (nAMD, DME, RVO) 1,024 +13 652 +4 190 0 37 +39 145 +126 Tecentriq Cancer immunotherapy 811 +4 378 +6 202 -6 69 0 162 +14 Xolair 3 Chronic hives, food allergies 708 +26 708 +26 - - - - - - Phesgo Breast cancer 686 +27 159 +2 206 +7 42 +23 279 +78 Perjeta 3 Breast cancer 672 -11 263 -12 119 -15 12 -19 278 -9 Actemra/RoActemra 3 RA, COVID-19 534 -4 248 -3 124 -16 66 +9 96 +5 Evrysdi Spinal muscular atrophy 464 +19 160 +15 159 +13 18 +4 127 +40 Kadcyla 3 Breast cancer 439 -4 156 -11 123 -6 19 +6 141 +5 Polivy Blood cancer 407 +26 171 +26 63 -32 46 +24 127 +120 Alecensa Lung cancer 401 +12 105 -7 63 -5 43 +4 190 +39 MabThera/Rituxan 3 Blood cancer, RA 292 +10 183 +16 31 -8 3 -6 75 +6 Activase/TNKase 3 Cardiac diseases 255 -2 244 -2 - - - - 11 -4 Gazyva/Gazyvaro 3 Blood cancer, lupus nephritis 247 +10 115 +1 57 -2 9 +28 66 +45 Herceptin 3 Breast and gastric cancer 234 -12 44 -16 69 -7 1 -24 120 -14 Avastin 3 Various cancer types 224 -9 59 -15 14 +3 21 -29 130 -1 CellCept 3 Immunosuppressant 99 +10 4 -5 28 -14 9 -16 58 +37 Enspryng Acute inflammation of brain, spinal cord and optic nerves 96 +31 22 +20 11 +20 35 +13 28 +93 Columvi Blood cancer 95 +77 43 +35 21 +84 - - 31 +204 DME: diabetic macular edema / nAMD: neovascular or ‘wet’ age-related macular degeneration / RVO: retinal vein occlusion / RA: rheumatoid arthritis Diagnostics: key developments Product Milestone Elecsys NfL blood test Multiple sclerosis Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis (MS) The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis. This minimally invasive blood test enables greater patient access to monitoring of neuroinflammatory status versus current standard of care methods. By providing deeper insight into underlying neuroinflammatory activity, the Elecsys NfL blood test has the potential to enable effective MS monitoring and earlier clinical intervention. More information: Media Release , 13 April 2026 cobas MPX-E assay HIV and hepatitis viruses Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply The cobas MPX-E test provides four critical results (for HIV, HCV, HBV and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs. The new test delivers faster turnaround times and allows labs to implement hepatitis E (HEV) screening without requiring additional instrumentation. This assay is designed for use on the fully automated cobas x800 systems, enabling high-throughput screening with up to 8 hours of walk-away time. More information: Media Release , 30 March 2026 Diagnostics sales Sales CHF millions As % of sales % change January–March 2026 2025 2026 2025 At CER In CHF Diagnostics Division 3,253 3,491 100.0 100.0 +3 -7 Customer areas Core Lab 1,798 1,904 55.3 54.5 +4 -6 Molecular Lab 571 634 17.5 18.2 0 -10 Near Patient Care 465 536 14.3 15.4 -5 -13 Pathology Lab 419 417 12.9 11.9 +12 0 Regions Europe, Middle East, Africa 1,206 1,236 37.1 35.4 +3 -2 North America 1,073 1,154 33.0 33.1 +6 -7 Asia-Pacific 725 853 22.3 24.4 -5 -15 Latin America 249 248 7.6 7.1 +10 0 More information on Roche’s performance in the first three months of 2026: Q1 2026 presentation Appendix with tables About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit . All trademarks used or mentioned in this release are protected by law. References [1] CER (Constant Exchange Rates). The percentage changes at constant exchange rates are calculated using simulations by reconsolidating both the 2026 and 2025 results at constant exchange rates (the average rates for the year ended 31 December 2025). For the definition of CER, see page 178 of the Roche Finance Report 2025. [2] USD (US dollars). The percentage changes for selected sales figures at US dollars are calculated by translating both the 2026 and 2025 sales figures at the respective average US dollar exchange rate for the period in question. This supplementary information is provided to assist readers when assessing comparability with other companies. [3] Products launched before 2015. Cautionary statement regarding forward-looking statements This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, such as: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com Hans Trees, PhD Phone: +41 79 407 72 58 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Irène Stephan Phone: +41 79 377 83 75 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com Attachments Q1 appendix tables Media Investor Release Q1 2026 English